Company: MBIO
Filing Date: 2025-04-01
Form Type: 424B3
Source: 0001104659-25-030657
Chunk: 91

Company: MUSTANG BIO, INC.
Filing Date: 2025-04-01
Form: 424B3
Chunk 91
---
The patent position of biotechnology and pharmaceutical
companies generally is highly uncertain, involves complex legal and factual questions and has in recent years been the subject of
much litigation. In addition, no consistent policy regarding the breadth of claims allowed in pharmaceutical or biotechnology patents
has emerged to date in the U.S. The patent situation outside the U.S. is even more uncertain. The laws of foreign countries may not protect
our rights to the same extent as the laws of the U.S., and we may fail to seek or obtain patent protection in all major markets. For example,
European patent law restricts the patentability of methods of treatment of the human body more than U.S. law does. Publications of discoveries
in the scientific literature often lag behind the actual discoveries, and patent applications in the U.S. and other jurisdictions are
typically not published until 18 months after a first filing, or in some cases not at all. Therefore, we cannot know with certainty
whether we or our licensors were the first to make the inventions claimed in patents or pending patent applications that we own or licensed,
or that we or our licensors were the first to file for patent protection of such inventions. In the event that a third party has also
filed a U.S. patent application relating to our product candidates or a similar invention, depending upon the priority dates claimed
by the competing parties, we may have to participate in interference proceedings declared by the USPTO to determine priority of invention
in the U.S. We might also become involved in derivation proceedings in an event that a third party misappropriates one or more of our
inventions and files their own patent application directed to such one or more inventions. The costs of these proceedings could be substantial,
and it is possible that our efforts to establish priority of invention (or that a third party derived an invention from us) would be

<div align='center'>47</div>

​

Table of Contents

unsuccessful, resulting in a material adverse
effect on our U.S. patent position. As a result, the issuance, scope, validity, enforceability and commercial value of our patent
rights are highly uncertain. Our pending and future patent applications may not result in patents being issued which protect our technology
or products, in whole or in part, or which effectively prevent others from commercializing competitive technologies and products. Changes
in either the patent laws or interpretation of the patent laws in the U.S. and other countries may diminish the value of our patents or
narrow the scope of